Slate Medicines merges with Fulcrum, backed by $245M raise for migraine drugs

What's the deal? Fulcrum TherapeuticsDealroom has a profile for this one. Try Dealroom → and Slate Medicines have agreed to combine in an all-stock merger, creating a company focused on next-generation migraine therapies. The combined entity will operate as Slate Medicines and trade on Nasdaq under the ticker "SLTE."

The financing: Slate secured an oversubscribed $245 million private placement to close alongside the merger. The round is led by Frazier Life SciencesDealroom has a profile for this one. Try Dealroom →, with participation from ForbionDealroom has a profile for this one. Try Dealroom →, RA Capital Management, Deep Track CapitalDealroom has a profile for this one. Try Dealroom →, Foresite Capital, OrbiMed, RTW InvestmentsDealroom has a profile for this one. Try Dealroom →, and Mingxin CapitalDealroom has a profile for this one. Try Dealroom →.

The combined company's cash is expected to fund operations into 2029. Before closing, Fulcrum plans to declare a cash dividend to its pre-merger stockholders equal to net cash above $20.3 million.

What's the endgame? The merged company will advance Slate's pipeline, led by SLTE-1009, a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody for migraine prevention. The drug is designed to bind two neuropeptides central to migraine, offering potential efficacy over PACAP-only therapies.

SLTE-1009 was engineered for a longer half-life, enabling subcutaneous dosing with potential quarterly administration. It has cleared the way to enter Phase 1 trials in Australia, with initial safety data expected mid-2027. The financing will fund the drug through Phase 1 and a Phase 2 dose-range study in patients.

Why now? Fulcrum reached the deal after weighing strategic alternatives. "We are pleased to announce this transaction with Slate, which we believe represents the best path forward for our stockholders," said Alex C. Sapir, Fulcrum's president and chief executive officer.

The signal: "Migraine remains one of the most prevalent and disabling neurological diseases, yet millions of patients continue to be underserved by existing therapies," said Gregory Oakes, chief executive officer of Slate Medicines. The reverse merger gives Slate a Nasdaq listing and a funded runway to test whether dual-target biology can improve on today's migraine drugs.

Read more: MarketScreener

Image credit: Generated with Gemini